BioPharmSignal logoBioPharmSignal

Biotech News

Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference

Oculis (OCS)OculisConference / presentation

ZUG, Switzerland, July 02, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant unmet medical needs, announced today that

Related news

OCSOculis2026-06-08 19:25 EST

Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference

OCSOculis2026-05-29 19:06 EST

Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

BLTEBelite Bio2026-07-15 12:00 EST

Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

OKYOOKYO Pharma2026-07-21 13:00 EST

OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

OKYOOKYO Pharma2026-09-08 11:00 EST

OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference

TARSTarsus Pharmaceuticals2026-09-01 20:30 EST

Tarsus to Participate in Upcoming Investor Conferences

OTLKOutlook2026-08-27 13:01 EST

Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference

BLTEBelite Bio2026-06-02 12:00 EST

Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

SGHTSight Sciences2026-09-01 20:05 EST

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15

IRIXIRIDEX2026-06-09 20:05 EST

Iridex to Present at the Planet MicroCap Las Vegas 2026 Conference

View all latest news

Oculis

Neuro-Ophthalmology Focus Oculis is a global biopharmaceutical company developing therapies for neuro-ophthalmic and ophthalmic diseases. Its strategy is centered on late-stage programs that protect visual function or apply a precision-medicine approach to ocular inflammation. Privosegtor Neuroprotection Privosegtor is a neuroprotective...

Recent company news

OCSOculis2026-09-17 20:05 EST

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

OCSOculis2026-08-24 08:00 EST

First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis

OCSOculis2026-08-14 20:05 EST

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

OCSOculis2026-08-10 07:30 EST

Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company

OCSOculis2026-08-06 20:05 EST

Oculis Reports Q2 2026 Financial Results and Provides Company Update

Stock data

Close
9.98 USD
Market cap
742.17M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States